Patent ID: 8916535

Claim:
A method for the treatment of chronic fatigue syndrome and/or for the treatment of infection by a gamma-retrovirus in an individual in need thereof comprising the step of administering a therapeutically effective amount of a compound of Formula (I), or stereochemically isomeric forms thereof, to said individual, wherein n is an integer selected from 1 to 8; R 1 is selected from the group comprising hydrogen, hydroxyl, amino, —OSi(CH 3 ) 2 C(CH 3 ) 3 , C 1-6 alkyl, C 1-6 alkylcarbonyloxy and C 1-6 alkoxy; R 2 is selected from the group comprising hydrogen, C 1-6 alkyl, C 6-12 aryl and C 6-12 arylC 1-6 alkyl; each R 4 is independently selected from the group comprising hydrogen, hydroxyl, amino, —OSi(CH 3 ) 2 C(CH 3 ) 3 , C 1-6 alkyl, C 1-6 alkylcarbonyloxy and C 1-6 alkoxy; each R 5 is independently selected from the group comprising hydrogen, C 1-6 alkyl, C 6-12 aryl and C 6-12 arylC 1-6 alkyl; R 6 is selected from the group comprising hydrogen, C 1-6 alkyl, C 6-12 aryl and C 6-12 arylC 1-6 alkyl; R 3 is selected from the group comprising hydroxyl, and m is an integer selected from 1, 2 or 3, each R 7 is independently selected from the group comprising OH, SH, C 1-6 alkyl and C 1-6 alkoxy, and L 2 is selected from —NH— or methylene; L 1 is selected from C 1-6 alkylene or C 1-6 alkyleneoxy; X 1 is selected from N or + NR 8 , wherein R 8 is selected from the group comprising C 1-6 alkyl, C 6-12 aryl and C 6-12 arylC 1-6 alkyl; each X 2 is independently selected from N or + NR 8 , wherein R 8 is selected from the group comprising C 1-6 alkyl, C 6-12 aryl and C 6-12 arylC 1-6 alkyl; X 3 is selected from N or + NR 8 , wherein R 8 is selected from the group comprising C 1-6 alkyl, C 6-12 aryl and C 6-12 arylC 1-6 alkyl; and wherein at least one of R 2 , R 5 , R 6 or R 8 is selected from C 6-12 aryl or C 6-12 arylC 1-6 alkyl; or, a pharmaceutically acceptable salt thereof.